Therapeutic strategies in inflammasome mediated diseases of the liver

Journal of Hepatology

Volumn 58, Issue 5, 2013, Pages 1047-1052

  Hoque, Rafaz ^a   Vodovotz, Yoram ^b   Mehal, Wajahat ^a  

^a YALE UNIVERSITY   (United States)

^b MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[5 (2,3 DICHLOROPHENYL) 1H TETRAZOL 1 YL]METHYL]PYRIDINE; ADENOSINE TRIPHOSPHATE; ALLOPURINOL; CATHEPSIN B; CURCUMIN; CYTOKINE; ERITORAN; FEBUXOSTAT; FOSTAMATINIB; GLYCYRRHIZIC ACID; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; IRS 954; MELATONIN; MONOCLONAL ANTIBODY HMB 45; NIVOCASAN; PARACETAMOL; PLACEBO; PYRUVIC ACID DERIVATIVE; PYRUVIC ACID ETHYL ESTER; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIC ACID;

ALCOHOL LIVER DISEASE; ARTICLE; AUTOIMMUNE HEPATITIS; CELL NUCLEUS; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; HUMAN; KUPFFER CELL; LIVER DISEASE; LIVER INJURY; MEDIATOR; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHAGOLYSOSOME; PHAGOSOME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TOXIC HEPATITIS; TRANSCRIPTION REGULATION;

EID: 84876292214     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.12.017     Document Type: Note

References (49)

1. T. Uesugi, M. Froh, G.E. Arteel, B.U. Bradford, and R.G. Thurman Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice Hepatology 34 2001 101 108
2. J. Petrasek, S. Bala, and T. Csak IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice J Clin Invest 122 2012 3476 3489
3. K. Miura, Y. Kodama, and S. Inokuchi Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice Gastroenterology 139 2010 323 e7 334 e7
4. A. Tsung, R.A. Hoffman, and K. Izuishi Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells J Immunol 175 2005 7661 7668
5. Z.M. Bamboat, V.P. Balachandran, L.M. Ocuin, H. Obaid, G. Plitas, and R.P. DeMatteo Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury Hepatology 51 2010 621 632
6. H.C. Yohe, K.A. O'Hara, and J.A. Hunt Involvement of Toll-like receptor 4 in acetaminophen hepatotoxicity Am J Physiol Gastrointest Liver Physiol 290 2006 G1269 G1279
7. A.B. Imaeda, A. Watanabe, and M.A. Sohail Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome J Clin Invest 119 2009 305 314
8. R. Hoque, M.A. Sohail, and S. Salhanick P2X7 receptor-mediated purinergic signaling promotes liver injury in acetaminophen hepatotoxicity in mice Am J Physiol Gastrointest Liver Physiol 302 2012 G1171 G1179
9. H. Kono, C.J. Chen, F. Ontiveros, and K.L. Rock Uric acid promotes an acute inflammatory response to sterile cell death in mice J Clin Invest 120 2010 1939 1949
10. E. Seki, S. De Minicis, and C.H. Osterreicher TLR4 enhances TGF-beta signaling and hepatic fibrosis Nat Med 13 2007 1324 1332
11. A. Watanabe, A. Hashmi, and D.A. Gomes Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9 Hepatology 46 2007 1509 1518
12. S.G. Boaru, E. Borkham-Kamphorst, L. Tihaa, U. Haas, and R. Weiskirchen Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease J Inflamm (Lond) 9 2012 49
13. T. Kitazawa, T. Tsujimoto, H. Kawaratani, and H. Fukui Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats with d-galactosamine-induced acute severe liver injury J Gastroenterol Hepatol 24 2009 1089 1094
14. M. Tidswell, W. Tillis, and S.P. Larosa Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis Crit Care Med 38 2010 72 83
15. X. Wang, R. Sun, H. Wei, and Z. Tian HMGB1-TLR4-IL-23-IL-17A axis in drug-induced damage-associated lethal hepatitis: interaction of gammadelta T cells with macrophages Hepatology 57 2013 373 384
16. T.G. van Rossum, A.G. Vulto, W.C. Hop, and S.W. Schalm Pharmacokinetics of intravenous glycyrrhizin after single and multiple doses in patients with chronic hepatitis C infection Clin Ther 21 1999 2080 2090
17. S. Yasui, K. Fujiwara, A. Tawada, Y. Fukuda, M. Nakano, and O. Yokosuka Efficacy of intravenous glycyrrhizin in the early stage of acute onset autoimmune hepatitis Dig Dis Sci 56 2011 3638 3647
18. R. Yang, S. Zhang, A. Cotoia, N. Oksala, S. Zhu, and J. Tenhunen High mobility group B1 impairs hepatocyte regeneration in acetaminophen hepatotoxicity BMC Gastroenterol 12 2012 45
19. R.R. Zhou, H.B. Liu, and J.P. Peng High mobility group box chromosomal protein 1 in acute-on-chronic liver failure patients and mice with ConA-induced acute liver injury Exp Mol Pathol 93 2012 213 219
20. A. Tsung, T. Kaizu, and A. Nakao Ethyl pyruvate ameliorates liver ischemia-reperfusion injury by decreasing hepatic necrosis and apoptosis Transplantation 79 2005 196 204
21. R. Yang, T. Uchiyama, S.K. Watkins, X. Han, and M.P. Fink Ethyl pyruvate reduces liver injury in a murine model of extrahepatic cholestasis Shock 22 2004 369 375
22. R. Yang, X. Han, R.L. Delude, and M.P. Fink Ethyl pyruvate ameliorates acute alcohol-induced liver injury and inflammation in mice J Lab Clin Med 142 2003 322 331
23. E. Bennett-Guerrero, M. Swaminathan, and A.M. Grigore A phase II multicenter double-blind placebo-controlled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass J Cardiothorac Vasc Anesth 23 2009 324 329
24. H. Wang, D.X. Xu, J.W. Lv, H. Ning, and W. Wei Melatonin attenuates lipopolysaccharide (LPS)-induced apoptotic liver damage in d-galactosamine- sensitized mice Toxicology 237 2007 49 57
25. H. Cichoz-Lach, K. Celinski, P.C. Konturek, S.J. Konturek, and M. Slomka The effects of l-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis J Physiol Pharmacol 61 2010 577 580
26. D.C. Kim, W. Lee, and J.S. Bae Vascular anti-inflammatory effects of curcumin on HMGB1-mediated responses in vitro Inflamm Res 60 2011 1161 1168
27. Y. Fu, S. Zheng, J. Lin, J. Ryerse, and A. Chen Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation Mol Pharmacol 73 2008 399 409
28. W. Wongcharoen, S. Jai-Aue, and A. Phrommintikul Effects of curcuminoids on frequency of acute myocardial infarction after coronary artery bypass grafting Am J Cardiol 110 2012 40 44
29. H. Kawamura, F. Aswad, M. Minagawa, S. Govindarajan, and G. Dennert P2X7 receptors regulate NKT cells in autoimmune hepatitis J Immunol 176 2006 2152 2160
30. M.O. Taha, M.J. Simoes, and E.C. Noguerol Effects of allopurinol on ischemia and reperfusion in rabbit livers Transplant Proc 41 2009 820 823
31. H. Tsuda, N. Kawada, and J.Y. Kaimori Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress Biochem Biophys Res Commun 427 2012 266 272
32. A.A. Shigeoka, J.L. Mueller, and A. Kambo An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia-reperfusion injury J Immunol 185 2010 6277 6285
33. A. Canbay, A. Feldstein, E. Baskin-Bey, S.F. Bronk, and G.J. Gores The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse J Pharmacol Exp Ther 308 2004 1191 1196
34. P.J. Pockros, E.R. Schiff, and M.L. Shiffman Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C Hepatology 46 2007 324 329
35. A. Mignon, N. Rouquet, and M. Fabre LPS challenge in d-galactosamine- sensitized mice accounts for caspase-dependent fulminant hepatitis, not for septic shock Am J Respir Crit Care Med 159 1999 1308 1315
36. V. Ratziu, M.Y. Sheikh, and A.J. Sanyal A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis Hepatology 55 2012 419 428
37. K. Naoyuki, F. Shin, and H. Toshikazu Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study J Clin Rheumatol 17 2012 S35 S43
38. H.R. Schumacher Jr., M.A. Becker, and R.L. Wortmann Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial Arthritis Rheum 59 2008 1540 1548
39. S.M. Opal, C.J. Fisher Jr., and J.F. Dhainaut Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The interleukin-1 receptor antagonist sepsis investigator group Crit Care Med 25 1997 1115 1124
40. M.C. Genovese, A. Kavanaugh, and M.E. Weinblatt An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents Arthritis Rheum 63 2011 337 345
41. O. Gross, H. Poeck, and M. Bscheider Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence Nature 459 2009 433 436
42. A.F. Malik, R. Hoque, and X. Ouyang Inflammasome components Asc and caspase-1 mediate biomaterial-induced inflammation and foreign body response Proc Natl Acad Sci USA 108 2011 20095 20100
43. Y. Vodovotz, M. Csete, J. Bartels, S. Chang, and G. An Translational systems biology of inflammation PLoS Comput Biol 4 2008 e1000014
44. N.Y. Li, K. Verdolini, and G. Clermont A patient-specific in silico model of inflammation and healing tested in acute vocal fold injury PLoS One 3 2008 e2789
45. G. Nieman, D. Brown, and J. Sarkar A two-compartment mathematical model of endotoxin-induced inflammatory and physiologic alterations in swine Crit Care Med 40 2012 1052 1063
46. B. Riviere, Y. Epshteyn, D. Swigon, and Y. Vodovotz A simple mathematical model of signaling resulting from the binding of lipopolysaccharide with Toll-like receptor 4 demonstrates inherent preconditioning behavior Math Biosci 217 2009 19 26
47. G. An A model of TLR4 signaling and tolerance using a qualitative, particle-event-based method: introduction of spatially configured stochastic reaction chambers (SCSRC) Math Biosci 217 2009 43 52
48. G.C. An, and J.R. Faeder Detailed qualitative dynamic knowledge representation using a BioNetGen model of TLR-4 signaling and preconditioning Math Biosci 217 2009 53 63
49. A. Vandenbon, S. Teraguchi, S. Akira, K. Takeda, and D.M. Standley Systems biology approaches to toll-like receptor signaling Wiley Interdiscip Rev Syst Biol Med 4 2012 497 507